Dr. David W. Chitty, DO
Hematology & Oncology (Hematology & Oncology Physician)
450 Lakeville Rd, Monter Cancer Center Entrance B
Lake Success, NY 11042
- Medicare participating
At a glance
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 114
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 293978-1
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Shore University Hospital Manhasset, NY
- Long Island Jewish Medical Center New Hyde PArk, NY
Medical groups
- North Shore Health System Medical Faculty Group Practice Inc (164 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 114
- Services billed
- 784
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 349 | 55 |
| Established patient office or other outpatient visit, 30-39 minutes | 190 | 62 |
| Established patient office or other outpatient visit, 40-54 minutes | 98 | 48 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 74 | 25 |
| Established patient office or other outpatient visit, 20-29 minutes | 58 | 33 |
| Hospital discharge day management, more than 30 minutes | 13 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Lake Success, NY | 31 |
| Levofloxacin Other prescribers in Lake Success, NY | 23 |
| Cyclosporine Other prescribers in Lake Success, NY | 16 |
| Revlimid (lenalidomide) | 16 |
| Venclexta (venetoclax) | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 11 payments worth $7,670 in total to this clinician.
| Syndax Pharmaceuticals, Inc. | $4,228 |
|---|---|
| Sanofi US Services Inc. | $2,332 |
| Novartis Pharmaceuticals Corporation | $825 |
| Janssen Scientific Affairs, LLC | $150 |
| AstraZeneca Pharmaceuticals LP | $135 |
| Consulting Fee | $6,087 |
|---|---|
| Travel and Lodging | $1,168 |
| Food and Beverage | $415 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,780 |
| Sanofi US Services Inc. Oct 24, 2025 | Consulting Fee AYVAKIT · Gastroenterology | $2,332 |
| Novartis Pharmaceuticals Corporation Apr 10, 2025 | Consulting Fee SCEMBLIX · Oncology | $825 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO · in-kind | $687 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO · in-kind | $377 |
| Janssen Scientific Affairs, LLC Jul 11, 2025 | Consulting Fee TALVEY · Oncology | $150 |
| Syndax Pharmaceuticals, Inc. Jul 10, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO · in-kind | $104 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $51,006 in research payments for these studies, mostly to the institutions running them.
- STML-401-0423 - a phase ii multicenter open -label trial of tagraxofusp (tag) in combination with venetoclax and azacitidine (ven/aza) in adults with previously untreated CD123+ acute myeloid leukemia (aml) who are i…
Stemline Therapeutics Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.